Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells

The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer

(2016) Bok-Soon Lee et al.   ANNALS OF SURGICAL ONCOLOGY

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors

(2016) Sheri L. Moores et al.   CANCER RESEARCH

Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer

(2016) Tania Losanno et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic

(2015) Katerina Politi et al.   CANCER CELL

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling

(2015) A. Hultberg et al.   CANCER RESEARCH

Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies

(2015) A. Bertotti et al.   CLINICAL CANCER RESEARCH

Onartuzumab in lung cancer: the fall of Icarus?

(2015) Christian Rolfo et al.   Expert Review of Anticancer Therapy

Fc glycans of therapeutic antibodies as critical quality attributes

(2015) Dietmar Reusch et al.   GLYCOBIOLOGY

Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody

(2015) Stephen W. Jarantow et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities

(2015) Falk Nimmerjahn et al.   TRENDS IN IMMUNOLOGY

Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target

(2014) Eduardo Castanon et al.   CURRENT DRUG TARGETS

Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity

(2014) S. Herter et al.   JOURNAL OF IMMUNOLOGY

Controlled Fab-arm exchange for the generation of stable bispecific IgG1

(2014) Aran F Labrijn et al.   Nature Protocols

Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures

(2014) Baoping Guo et al.   PLoS One

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer

(2014) Joohyuk Sohn et al.   Journal of Cancer

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

(2013) J. Golay et al.   BLOOD

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity

(2013) Whitney Shatz et al.   mAbs

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

(2013) Omid Vafa et al.   METHODS

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity

(2013) R Castoldi et al.   ONCOGENE

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

(2013) A. F. Labrijn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Revisiting the Role of Glycosylation in the Structure of Human IgG Fc

(2012) M. Jack Borrok et al.   ACS Chemical Biology

Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function

(2012) K. D. Grugan et al.   JOURNAL OF IMMUNOLOGY

Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1

(2012) Thomas C. Nesspor et al.   JOURNAL OF MOLECULAR RECOGNITION

Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities

(2012) Shan Chung et al.   mAbs

Isolation and characterization of IgG1 with asymmetrical Fc glycosylation

(2011) S. Ha et al.   GLYCOBIOLOGY

Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition

(2011) M. B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort

(2011) Seiji Yano et al.   Journal of Thoracic Oncology

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Crosstalk in Met receptor oncogenesis

(2009) Andrea Z. Lai et al.   TRENDS IN CELL BIOLOGY

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

(2008) Z Tang et al.   BRITISH JOURNAL OF CANCER

Effector mechanisms of therapeutic antibodies against ErbB receptors

(2008) Matthias Peipp et al.   CURRENT OPINION IN IMMUNOLOGY